Industry Perspectives on the MTD: Growing Acceptance in Clinical Development Programs
Gespeichert in:
Veröffentlicht in: | Journal of clinical pharmacology 2000-11, Vol.40 (11), p.1191-1197 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1197 |
---|---|
container_issue | 11 |
container_start_page | 1191 |
container_title | Journal of clinical pharmacology |
container_volume | 40 |
creator | Chaikin, Philip |
description | |
doi_str_mv | 10.1177/009127000004001103 |
format | Article |
fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_009127000004001103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JCPH5811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4313-609f876077423e6dd6c9b34b35c633bb999af1e9a9c76ee82e1ab10b4514093f3</originalsourceid><addsrcrecordid>eNqNkE9PwyAYh4nR6PzzBTwYvkAVCoXiTTedmqk7aEy8EMreumrXNtBt7ttL3aIHL3J5yZvn-QV-CB1TckqplGeEKBpL0h1OCKWEbaEeTZI44oLwbdTrgKgj9tC-9--BETyhu2gvsDJhhPfQ8201mfvWrfAYnG_AtsUCPK4r3E4B3z8NzvHQ1cuiesMX1kLTmsoCLircL4uqsKbEA1hAWTczqFo8dvWbMzN_iHZyU3o42swD9Hx99dS_iUaPw9v-xSiynFEWCaLyVAoiJY8ZiMlEWJUxnrHECsayTCllcgrKKCsFQBoDNRklWfgEJ4rl7ADF61zrau8d5Lpxxcy4laZEdx3pvx0F6WQtNfNsBpNfZVNKAPgaWNZlG1r5KOdLcHoKpmyn-jsqJEYx-Q4Mt27V5aYbrShh9Y-X6Lv--CZJKQ1qtFYL38Lnj2rchxaSyUS_PAz1KL18SejrQI_YF6wqjqc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Industry Perspectives on the MTD: Growing Acceptance in Clinical Development Programs</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chaikin, Philip</creator><creatorcontrib>Chaikin, Philip</creatorcontrib><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1177/009127000004001103</identifier><identifier>PMID: 11075304</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Clinical Trials as Topic ; Drug Industry ; Humans ; Maximum Tolerated Dose ; Neoplasms - drug therapy</subject><ispartof>Journal of clinical pharmacology, 2000-11, Vol.40 (11), p.1191-1197</ispartof><rights>2000 American College of Clinical Pharmacology</rights><rights>2000 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4313-609f876077423e6dd6c9b34b35c633bb999af1e9a9c76ee82e1ab10b4514093f3</citedby><cites>FETCH-LOGICAL-c4313-609f876077423e6dd6c9b34b35c633bb999af1e9a9c76ee82e1ab10b4514093f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1177%2F009127000004001103$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1177%2F009127000004001103$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11075304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaikin, Philip</creatorcontrib><title>Industry Perspectives on the MTD: Growing Acceptance in Clinical Development Programs</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><subject>Clinical Trials as Topic</subject><subject>Drug Industry</subject><subject>Humans</subject><subject>Maximum Tolerated Dose</subject><subject>Neoplasms - drug therapy</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE9PwyAYh4nR6PzzBTwYvkAVCoXiTTedmqk7aEy8EMreumrXNtBt7ttL3aIHL3J5yZvn-QV-CB1TckqplGeEKBpL0h1OCKWEbaEeTZI44oLwbdTrgKgj9tC-9--BETyhu2gvsDJhhPfQ8201mfvWrfAYnG_AtsUCPK4r3E4B3z8NzvHQ1cuiesMX1kLTmsoCLircL4uqsKbEA1hAWTczqFo8dvWbMzN_iHZyU3o42swD9Hx99dS_iUaPw9v-xSiynFEWCaLyVAoiJY8ZiMlEWJUxnrHECsayTCllcgrKKCsFQBoDNRklWfgEJ4rl7ADF61zrau8d5Lpxxcy4laZEdx3pvx0F6WQtNfNsBpNfZVNKAPgaWNZlG1r5KOdLcHoKpmyn-jsqJEYx-Q4Mt27V5aYbrShh9Y-X6Lv--CZJKQ1qtFYL38Lnj2rchxaSyUS_PAz1KL18SejrQI_YF6wqjqc</recordid><startdate>200011</startdate><enddate>200011</enddate><creator>Chaikin, Philip</creator><general>Blackwell Publishing Ltd</general><general>SAGE Publications</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200011</creationdate><title>Industry Perspectives on the MTD: Growing Acceptance in Clinical Development Programs</title><author>Chaikin, Philip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4313-609f876077423e6dd6c9b34b35c633bb999af1e9a9c76ee82e1ab10b4514093f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Clinical Trials as Topic</topic><topic>Drug Industry</topic><topic>Humans</topic><topic>Maximum Tolerated Dose</topic><topic>Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaikin, Philip</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaikin, Philip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Industry Perspectives on the MTD: Growing Acceptance in Clinical Development Programs</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2000-11</date><risdate>2000</risdate><volume>40</volume><issue>11</issue><spage>1191</spage><epage>1197</epage><pages>1191-1197</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>11075304</pmid><doi>10.1177/009127000004001103</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-2700 |
ispartof | Journal of clinical pharmacology, 2000-11, Vol.40 (11), p.1191-1197 |
issn | 0091-2700 1552-4604 |
language | eng |
recordid | cdi_crossref_primary_10_1177_009127000004001103 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Clinical Trials as Topic Drug Industry Humans Maximum Tolerated Dose Neoplasms - drug therapy |
title | Industry Perspectives on the MTD: Growing Acceptance in Clinical Development Programs |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A14%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Industry%20Perspectives%20on%20the%20MTD:%20Growing%20Acceptance%20in%20Clinical%20Development%20Programs&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Chaikin,%20Philip&rft.date=2000-11&rft.volume=40&rft.issue=11&rft.spage=1191&rft.epage=1197&rft.pages=1191-1197&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1177/009127000004001103&rft_dat=%3Cwiley_cross%3EJCPH5811%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11075304&rfr_iscdi=true |